FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to immunogenic epitopes of URLC10, obtaining modified epitope peptides URLC10, which in the presence of antigen-presenting cells (APC) expressing HLA-A*1101 or HLA-A*0301, have higher ability of inducing cytotoxic T-lymphocytes (CTL) than the wild-type URLC10 peptide epitope peptide.
EFFECT: invention can be used in medicine for treating a patient suffering from cancer.
18 cl, 8 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CDCA1-DERIVED PEPTIDE AND VACCINE CONTAINING SAME | 2015 |
|
RU2699543C2 |
| KOC1-DERVIED PEPTIDE AND VACCINE INCLUDING SAME | 2015 |
|
RU2699542C2 |
| PEPTIDE OBTAINED FROM DEPDC1 AND VACCINE CONTAINING IT | 2016 |
|
RU2765574C2 |
| PEPTIDE, OBTAINED FROM MPHOSPH1, AND INCLUDING ITS VACCINE | 2016 |
|
RU2731099C2 |
| PHARMACEUTICAL, CONTAINING EPITOPE PEPTIDES HIG2 AND URLC10, FOR CANCER TREATMENT, METHODS AND MEANS FOR INDUCTION OF ANTIGEN-PRESENTING CELL AND CYTOTOXIC T-LYMPHOCYTE (CTL), ANTIGEN-PRESENTING CELL AND CTL, OBTAINED THEREOF, METHOD AND MEANS OF IMMUNE ANTI-CANCER RESPONSE | 2009 |
|
RU2529373C2 |
| PEPTIDE DERIVED FROM FOXM1, AND INCLUDING ITS VACCINE | 2016 |
|
RU2738418C2 |
| CDCA1 EPITOPE PEPTIDES AND VACCINES CONTAINING SAME | 2009 |
|
RU2502740C2 |
| MODIFIED MELK PEPTIDES AND VACCINES CONTAINING LATTER | 2011 |
|
RU2580035C2 |
| UBE2T PEPTIDE AND VACCINES CONTAINING THE SAME | 2013 |
|
RU2663350C2 |
| CDC45L PEPTIDES AND VACCINES CONTAINING SAME | 2010 |
|
RU2562160C2 |
